Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165226 | 0.88 | HSD11B1 (0.59) | HSD11B1NR1H3 | |
| SCHEMBL15459955 | 0.81 | HSD11B1 (0.53) | HSD11B1NR1H3 | |
| SCHEMBL25753451 | 0.81 | HSD11B1 (0.53) | HSD11B1NR1H3 | |
| SCHEMBL27652960 | 0.81 | TRPV1 (0.40) | HSD11B1NR1H3 | |
| SCHEMBL12334058 | 0.80 | TRPV1 (0.70) | — | |
| SCHEMBL5530921 | 0.79 | MLYCD (0.52) | HSD11B1NR1H3 | |
| SCHEMBL11920703 | 0.79 | MLYCD (0.52) | HSD11B1NR1H3 | |
| SCHEMBL14697375 | 0.79 | HSD11B1 (0.72) | HSD11B1NR1H3 | |
| SCHEMBL8482502 | 0.79 | ESR1 (0.56) | HSD11B1 | |
| SCHEMBL2102455 | 0.79 | HSD11B1 (0.72) | HSD11B1NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216361-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2023-09-07 | — | — | US | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8329904-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2430023-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277527-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | HSD11B1 87/4885NR1H3 18/4885 |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | HSD11B1 87/4885NR1H3 18/4885 |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | HSD11B1 189/4885NR1H3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.